4th Quarter - Report

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 21, 2014 $280,000 Replaced
4th Quarter - Termination Amendment Apr 8, 2014 $280,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.J.Res. 59 (113th), H.Con.Res. 25 (113th), S.Con.Res. 8 (113th)

Budget/Appropriations BUD

S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.J.Res. 59 (113th), S.Con.Res. 8 (113th), H.Con.Res. 25 (113th)

Pharmacy PHA

Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3204 (113th), S. 959 (113th), H.R. 1919 (113th), H.R. 2186 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.